PURAPHARM (01498) is planning to issue 46.512 million shares to BAGI Research Limited, raising approximately HK$2000.02 million.

PURAPHARM (01498) announced on July 25, 2025 (after trading hours) that the company has entered into a patent license agreement with licensor BAGI Research Limited. Under this agreement, the licensor has conditionally agreed to grant the company an exclusive, non-transferable license for patented intellectual property. In consideration for the license, the company has conditionally agreed to issue and issue consideration shares to the licensor as a one-time non-refundable license fee of HK$40.2 million. On July 25, 2025, the company also entered into a subscription agreement with subscribers. Under this agreement, the subscribers have conditionally agreed to subscribe, and the company has conditionally agreed to issue and issue 46.512 million subscription shares at a subscription price of HK$0.43 per share. The total amount of funds raised from the subscription will be HK$200.02 million. The issue price represents a discount of approximately 5.5% compared to the closing market price of HK$0.455 per share on the Stock Exchange of Hong Kong on July 24, 2025 (the last trading day before the patent license agreement date).